59856-06-3

Basic information

• Product Name: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE
• Synonyms: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE;AKOS 91915;5-ACETAMIDOINDANE;n-2,3-dihydro-1h-inden-5-ylacetamide;N-(2,3-dihydro-1H-inden-6-yl)acetamide;N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(WXG01310)
• CAS NO: 59856-06-3
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.23
• Product Categories: Amines;Fused Ring Systems
• Mol File: 59856-06-3.mol
• Article Data: 33

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 357.1 °C at 760 mmHg
• Flash Point: 210.8 °C
• Appearance: /
• Density: 1.155 g/cm³
• Vapor Pressure: 2.8E-05mmHg at 25°C
• Refractive Index: 1.611
• PKA: 15.13±0.20(Predicted)
• CAS DataBase Reference: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(59856-06-3)
• EPA Substance Registry System: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(59856-06-3)

Safety Data

• Hazardous Substances Data: 59856-06-3(Hazardous Substances Data)

Usage

General Description

N1-(2,3-Dihydro-1H-inden-5-yl)acetamide is a chemical compound with the molecular formula C12H13NO. It is an amide derivative of 2,3-dihydro-1H-indene-5-carboxylic acid, and is also known as 2,3-dihydro-5-indenylacetamide. N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE is used in the pharmaceutical industry as a potential drug molecule or as a precursor for the synthesis of other bioactive compounds. It has been studied for its potential antifungal and anticancer properties, and is also used as a building block for the synthesis of various heterocyclic compounds. N1-(2,3-Dihydro-1H-inden-5-yl)acetamide is a white crystalline solid at room temperature and is typically stored and handled in dry, cool conditions to avoid degradation.

InChI:InChI=1/C11H13NO/c1-8(13)12-11-6-5-9-3-2-4-10(9)7-11/h5-7H,2-4H2,1H3,(H,12,13)

Upstream product

• 36795-33-2 1-(indan-5-yl)ethanone oxime 
• 24425-40-9 indan-5-amine 
• 108-24-7 acetic anhydride 
• 64-19-7 acetic acid 
• 41734-55-8 5-nitro-1H-indene 
• 119273-81-3 6-nitro-2,3-dihydro-1H-inden-1-ol 
• 98-09-9 benzenesulfonyl chloride 
• 2620-44-2 5-nitro-1,3-benzodioxole 
• 7436-07-9 5-nitroindane 
• 18312-45-3 propan-2-one O-acetyl oxime 
• 75-36-5 acetyl chloride 

Downstream Products

• 860183-29-5 2-(6-acetylamino-indan-5-carbonyl)-benzoic acid 
• 855880-59-0 N-(6-chloroacetyl-indan-5-yl)-acetamide 
• 24425-40-9 indan-5-amine 
• 157701-33-2 5-acetylamino-6-bromoindane 
• 3470-54-0 5-aminoindan-1-one 
• 851107-86-3 4,5-diamino-indan-1-one 
• 909555-35-7 7-benzyl-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 851107-84-1 N-(6-bromo-4-nitro-1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide 
• 851107-88-5 7-(4-fluoro-benzylidene)-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 851107-89-6 7-(4-fluorobenzyl)-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 158205-18-6 5-Acetylamino-6-bromo-1-indanone 
• 174487-71-9 4-{N-[(6R/6S)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid 
• 157701-05-8 N-(4-{N-[(6S)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoyl)-L-glutamic acid 
• 157701-04-7 N-(4-{N-[(6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoyl)-L-glutamic acid 

Relevant articles and documents

COMPOUNDS

The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl triazoles. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

no abstract published